Lanreotide 60 mg, a longer-acting somatostatin analog: Tumor shrinkage and hormonal normalization in acromegaly

被引：21
作者：
Cozzi R. [1 ,2 ]
Barausse M. [1 ,2 ]
Sberna M. [3 ]
Lodrini A. [4 ]
Franzini A. [4 ]
Lasio G. [4 ]
Attanasio R. [1 ,2 ]
机构：
[1] Division of Endocrinology, Niguarda Hospital
[2] Division of Endocrinology, Niguarda Hospital
[3] Division of Neuroradiology, Niguarda Hospital
[4] Division of Neurosurgery, Neurologic Institute Carlo Besta, Milan
来源：
Pituitary | 2000年 / 3卷 / 4期
关键词：
Acromegaly; GH; IGF-I; Lanreotide; Somatostatin analogs; Tumor shrinkage;
D O I：
10.1023/A:1012832230598
中图分类号：
学科分类号：
摘要：
Background: Somatostatin analogues are nowadays the milestone in the medical treatment of acromegaly. We evaluated the effects of a new 60 mg longer-acting formulation of lanreotide (LAN60) on GH/IGF-I levels and tumor size. Patients: Twenty-one acromegalics entered a prospective monocentric open study. Eight were consecutive "de novo" patients (group I). Thirteen patients sensitive to SA (GH levels < 2.5 μg/l and/or IGF-I normalization on chronic LAN 30 mg (LAN30) treatment) were switched to LAN60 (group II). Protocol: LAN60 was administered IM for 6 cycles at 28 day intervals. In group I when GH/IGF-I remained pathological, the intervals were shortened to 21 days for the last three cycles. Controls: GH/IGF-I at the end of the 1st, 3rd and 6th cycle; MRI at the end of the study in all patients in group I bearing an adenoma. Results: Group I.GH (p = 0.00638, below 2.5 μg/l in two patients) and IGF-I (p = 0.0289, normalized in 5) significantly decreased. In one of two patients shortening the LAN60 schedule was more effective in suppressing GH/IGF-I. Group II. No change in GH and IGF-I levels was observed with the administration of LAN60, instead of LAN30. On LAN60 GH remained below 2.5 μg/l in 8/10 patients and IGF-I normal in 11/11 patients that had attained those values on LAN30. Tumor markedly shrank (23% to 64% vs basal), from 1400 (664-1680) mm3 to 520 (500-960) mm3 (median, interquartile, p = 0.0218) in all the 5 evaluable patients. Conclusion: LAN60 is a very effective and longer-lasting formulation for the treatment of acromegaly. A closer administration schedule might achieve greater efficacy. Its effectiveness in shrinking tumor opens new perspectives in the therapy of acromegaly.
引用
收藏
页码：231 / 238
页数：7
相关论文
共 26 条
  • [11] Al-Maskari M., Gebbie J., Kendall-Taylor P., The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly, Clin Endocrinol (Oxf), 45, pp. 415-421, (1996)
  • [12] Giusti M., Gussoni G., Cuttica C.M., Giordano G., Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study, J Clin Endocrinol Metab, 81, pp. 2089-2097, (1996)
  • [13] Caron P., Morange-Ramos I., Cogne M., Jaquet P., Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide, J Clin Endocrinol Metab, 82, pp. 18-22, (1997)
  • [14] Colao A., Marzullo P., Ferone D., Marino V., Pivonello R., Di Somma C., Di Sarno A., Giaccio A., Lombardi G., Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly, J Endocrinol Invest, 22, pp. 40-47, (1999)
  • [15] Suliman M., Jenkins R., Ross R., Powell T., Battersby R., Cullen D.R., Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide, J Endocrinol Invest, 22, pp. 409-418, (1999)
  • [16] Attanasio R., Barausse M., Cozzi R., GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide, J Endocrinol Invest, 24, pp. 209-216, (2001)
  • [17] Newman C.B., Medical therapy of acromegaly, Endocrinol Metab Clin N Amer, 28, pp. 171-190, (1999)
  • [18] Barkan A.L., Lloyd R.V., Chandler W.F., Hatfield M.K., Gebarski S.S., Kelch R.P., Beitins I.Z., Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate, J Clin Endocrinol Metab, 67, pp. 1040-1048, (1988)
  • [19] Barkan A.L., Halasz I., Dornfeld K.J., Jaffe C.A., Friberg R.D., Chandler W.F., Sandler H.M., Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly, J Clin Endocrinol Metab, 82, pp. 3187-3191, (1997)
  • [20] Baldelli R., Ferretti E., Jaffrain-Rea M.L., Iacobellis G., Miniti G., Caracciolo B., Moroni C., Cassone R., Gulino A., Tamburrano G., Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients, J Clin Endocrinol Metab, 84, pp. 527-532, (1999)
123